We did get real news on Monday but it didn't come from Clinuvel. Clinuvel had two potential competitors for EPP treatment that many believed were less than 2-3 years away from being approved. Both Bitopertin (Disc) and Dersimelagon (Tanabe) Phase II & Phase III trials failed in the past few months. Both may choose to start over or they may abandon their hopes to one day treat EPP patients altogether. Clinuvel has a monopoly on EPP treatment for many years to come. That is news by itself.
We did get real news on Monday but it didn't come from Clinuvel....
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.69 |
Change
0.060(0.44%) |
Mkt cap ! $685.3M | |||
| Open | High | Low | Value | Volume |
| $13.63 | $13.94 | $13.59 | $674.1K | 49.18K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1200 | $13.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.75 | 179 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |